Reports
Reports
Sale
The calciphylaxis market was valued at USD 3.9 billion in 2023 driven by the incidence of chronic kidney disease (CKD) across the 8 major markets. The market is expected to grow at a CAGR of 11.59% during the forecast period 2024-2032 and attain a market value of USD 10.3 billion by 2032.
Calciphylaxis, also called calcific uremic arteriolopathy (CUA), is an uncommon, excruciating, condition where calcium gets accumulated in blood vessels, causing blockage of blood flow and resulting in eventual skin and tissue breakdown and death. These deposits can form in regions like the eyes, lungs, brain, muscles, and intestines. When it impacts the outer tissue layers, it forms an open wound that leads to the death of skin and tissue, causing the damage to expand outwards. It takes a significant amount of time for these injuries to recover and could potentially result in severe issues.
There are two kinds of calciphylaxis, namely uremic and non-uremic. Uremic is more common, impacting patients receiving dialysis for advanced kidney disease. Non-uremic is less common, affecting people in early kidney disease stages, people with recent kidney injury, or those without kidney issues. Both categories are associated with the hardening of tiny blood vessels due to calcification. Calciphylaxis can be caused by various factors, such as elevated parathyroid hormone from kidney problems, disrupted calcium balance from kidney failure, excessive phosphorus levels regulated by the kidneys, specific cancers, and trauma from injuries or medical procedures.
Rising Incidence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)
The rising occurrence of CKD and ESRD is increasing the need for calciphylaxis treatment. Calciphylaxis, a serious condition marked by blood vessel calcification in the skin and fat, predominantly impacts individuals with advanced chronic kidney disease and end-stage renal disease. Approximately 37 million Americans, or more than 1 in 7 U.S. adults, are impacted by chronic kidney disease (CKD). In the United States, approximately 550,000 individuals are undergoing dialysis, resulting in an average of nearly 2,000 cases of calciphylaxis occurring annually.
Rising incidence of diabetes and hypertension is also adding to the risk of developing calciphylaxis. This will increase the need for medical treatment along with upgraded methods of diagnosis, and care plans to handle calciphylaxis effectively. Pharmaceutical and medical device companies are also working on developing focused therapies, including novel drugs and wound care items, to improve patient results.
Advancements in Diagnostic Techniques to Address Rising Calciphylaxis Market Demand
Improvements in diagnostic methods have significantly enhanced the capacity to meet the growing needs in the calciphylaxis management. Historically, diagnosing this rare condition with vascular calcification and tissue necrosis has been challenging, but technological advances are now improving the process. High-quality ultrasound, CT angiography, and PET scans offer accurate imaging of calcific deposits in blood vessels, assisting in early detection and treatment preparation. Combining AI algorithms with imaging methods improves diagnostic precision by detecting subtle patterns. Biomarkers created from proteomic and genomic studies provide extra diagnostic options for medical professionals. These developments speed up diagnosis, customize treatment, and enhance patient results while lowering healthcare expenses. The advancement of diagnostic techniques is transforming the treatment of calciphylaxis to efficiently address market needs.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Key Trends | Impact |
Increasing Awareness About the Condition | Enhanced understanding among healthcare professionals and individuals is resulting in early recognition and treatment, thereby, enhancing patient results and decreasing healthcare expenses. This recognition also promotes the creation of novel treatments and detection instruments. |
Epidemiological Studies | Epidemiological research plays a crucial role in the calciphylaxis market by uncovering disease incidence, and potential causes. They assist in recognizing groups that are at high risk of developing the condition. This also influences diagnostics and the allocation of resources. It can also help in shaping healthcare policies. |
Therapeutic Advances | The treatment options and outcomes for patients with calciphylaxis are being transformed by therapeutic advances. In the historical period, treatment options were limited, however, advancements in understanding the condition's pathophysiology have resulted in the development of targeted therapies such as sodium thiosulfate. Enhanced wound care and additional therapies have also played a key role in managing symptoms and enhancing patients' quality of life. |
Surge in Biomarker Research for Early Detection | Research on biomarkers is crucial for comprehending and treating calciphylaxis. Recognizing biomarkers can enhance diagnosis, forecast results, and create focused treatments. Biomarkers such as increased MGP levels help with early identification and supervision, resulting in timely action. |
Market Breakup by Treatment Type
Market Breakup by Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation by Treatment Type to Witness Substantial Growth
The market segmentation based on treatment types includes drug therapy, hyperbaric oxygen therapy and surgery. Drug therapy is expected to hold the largest share of the market in the coming years. Treatment for calciphylaxis involves the use of medications such as calcium and phosphate binders, vitamin D analogues, sodium thiosulfate, anticoagulants, and pain relief drugs. Hyperbaric oxygen therapy is a treatment that entails inhaling pure oxygen in a chamber with increased pressure to stimulate the healing of wounds. Treatment for calciphylaxis can involve surgery such as debridement, skin grafting, and parathyroidectomy. The goal of these treatments is to control the mineral imbalance, enhance wound healing, and address abnormalities in mineral metabolism linked to calciphylaxis.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India.
The United States is estimated to dominate the calciphylaxis market due to its strong healthcare system, advanced diagnostic tools, emphasis on high CKD rates, pharmaceutical therapies, and wound management. The healthcare market is mainly shaped by substantial healthcare expenditures and extensive insurance coverage, which guarantees patients can obtain essential treatments. Initiatives aimed at informing the masses about the disease occurrence is amongst the major market trends. For instance, the calciphylaxis program at Massachusetts General Hospital involves multiple specialists who offer thorough evaluations and treatments to improve patient outcomes by emphasizing early diagnosis, individualized care, prevention, and cutting-edge research.
The EU-4 and UK market is also experiencing robust growth because of aging population, and government-backed healthcare systems providing support via reimbursement programs. Calciphylaxis is found in 1 out of every 10,000 people in the UK and 1 out of every 600 individuals undergoing dialysis, typically identified in elderly women. There is a significant focus on cutting-edge treatments, and partnerships with pharmaceutical companies and research institutions to create new products.
The market in Japan and India is driven by higher healthcare spending and better access to specialized treatment, a rise in chronic kidney disease and diabetes cases, government efforts to enhance healthcare facilities, and pharmaceutical firms focusing on developing affordable therapies for unmet medical needs.
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis as well as strategic initiatives including recent partnerships and collaborations by the leading players. The major companies in the market are as follows:
Amgen Inc.
Amgen Inc. is a biopharmaceutical company established in 1980 and headquartered in California, USA. It focuses on discovering, developing, manufacturing, and marketing novel medications for heart diseases, cancer, inflammation, bone, brain, and kidney diseases. The company utilizes advanced human genetics to create tailored products for treating diseases and delivers them through pharmaceutical distributors in the U.S. In 2021, the FDA approved its innovative therapy Sensipar for chronic kidney illness.
Smith & Nephew plc
Smith & Nephew plc is a UK-based company that focuses on producing medical devices and is in Watford, England. The company specializes in orthopedic reconstruction, trauma, sports medicine, ENT, and wound care. They produce knee and hip implants, robotic-assisted technologies, and trauma products for stabilizing fractures and correcting deformities.
BSN Medical
BSN Medical was established in 2001 and is a top player in the healthcare industry. It specializes in compression therapy, wound care, and orthopedics through well-known brands such as Leukoplast and Cutimed.
ConvaTec Inc
Convatec Group plc, known as Convatec, is a medical products company based in London and was established in 1978. Their expertise lies in cutting-edge wound care, ostomy care, continence, and infusion care, and they are a worldwide FTSE 250 corporation dedicated to addressing chronic conditions with top positions in multiple healthcare fields.
Other players in the market include Hope Pharmaceuticals, Ltd, and Sanifit Therapeutics S.A., among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Calciphylaxis Market Overview: 8 Major Market
3.1 Calciphylaxis Market Historical Value (2017-2023)
3.2 Calciphylaxis Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Calciphylaxis Market: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Calciphylaxis Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Calciphylaxis Market Landscape: 8 Major Market*
8.1 Calciphylaxis Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Calciphylaxis Market: Product Landscape
8.2.1 Analysis by Treatment Type
9 Calciphylaxis Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Calciphylaxis: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Calciphylaxis Market Segmentation: 8 Major Markets
12.1 Calciphylaxis Market by Treatment Type
12.1.1 Market Overview
12.1.2 Drug Therapy
12.1.3 Hyperbaric Oxygen Therapy
12.1.4 Surgery
12.2 Calciphylaxis Market by Type
12.2.1 Market Overview
12.2.2 Non-Uremic Calciphylaxis
12.2.3 Uremic Calciphylaxis
12.3 Calciphylaxis Market by End User
12.3.1 Market Overview
12.3.2 Hospitals and Clinics
12.3.3 Homecare
12.3.4 Others
12.4 Calciphylaxis Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Calciphylaxis Market (2017-2032)
13.1 United States Calciphylaxis Market Historical Value (2017-2023)
13.2 United States Calciphylaxis Market Forecast Value (2024-2032)
13.3 United States Calciphylaxis Market by Treatment Type
13.3.1 Market Overview
13.3.2 Drug Therapy
13.3.3 Hyperbaric Oxygen Therapy
13.3.4 Surgery
13.4 United States Calciphylaxis Market by Type
13.4.1 Market Overview
13.4.2 Non-Uremic Calciphylaxis
13.4.3 Uremic Calciphylaxis
13.5 United States Calciphylaxis Market by End User
13.5.1 Market Overview
13.5.2 Hospitals and Clinics
13.5.3 Homecare
13.5.4 Others
14 EU-4 and United Kingdom Calciphylaxis Market (2017-2032)
14.1 EU-4 and United Kingdom Calciphylaxis Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Calciphylaxis Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Calciphylaxis Market by Treatment Type
14.3.1 Market Overview
14.3.2 Drug Therapy
14.3.3 Hyperbaric Oxygen Therapy
14.3.4 Surgery
14.4 EU-4 and United Kingdom Calciphylaxis Market by Type
14.4.1 Market Overview
14.4.2 Non-Uremic Calciphylaxis
14.4.3 Uremic Calciphylaxis
14.5 EU-4 and United Kingdom Calciphylaxis Market by End User
14.5.1 Market Overview
14.5.2 Hospitals and Clinics
14.5.3 Homecare
14.5.4 Others
15 Japan Calciphylaxis Market
15.1 Japan Calciphylaxis Market Historical Value (2017-2023)
15.2 Japan Calciphylaxis Market Forecast Value (2024-2032)
15.3 Japan Calciphylaxis Market by Treatment Type
15.3.1 Market Overview
15.3.2 Drug Therapy
15.3.3 Hyperbaric Oxygen Therapy
15.3.4 surgery
15.4 Japan Calciphylaxis Market by Type
15.4.1 Market Overview
15.4.2 Non-Uremic Calciphylaxis
15.4.3 Uremic Calciphylaxis
15.5 Japan Calciphylaxis Market by End User
15.5.1 Market Overview
15.5.2 Hospitals and Clinics
15.5.3 Homecare
15.5.4 Others
16 India Calciphylaxis Market
16.1 India Calciphylaxis Market (2017-2032) Historical Value (2017-2023)
16.2 India Calciphylaxis Market (2017-2032) Forecast Value (2024-2032)
16.3 India Calciphylaxis Market by Treatment Type
16.3.1 Market Overview
16.3.2 Drug Therapy
16.3.3 Hyperbaric Oxygen Therapy
16.3.4 Surgery
16.4 India Calciphylaxis Market by Type
16.4.1 Market Overview
16.4.2 Non-Uremic Calciphylaxis
16.4.3 Uremic Calciphylaxis
16.5 India Calciphylaxis Market by End User
16.5.1 Market Overview
16.5.2 Hospitals and Clinics
16.5.3 Homecare
16.5.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Amgen Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisition
23.2.5 Certifications
23.3 Smith & Nephew plc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisition
23.3.5 Certifications
23.4 BSN Medical
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisition
23.4.5 Certifications
23.5 Hope Pharmaceuticals, Ltd
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisition
23.5.5 Certifications
23.6 ConvaTec Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisition
23.6.5 Certifications
23.7 Sanifit Therapeutics S.A.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisition
23.7.5 Certifications
24 Calciphylaxis Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.